Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | WHR1 | P49842 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13877444 | 0.94 | MEN1 (0.55) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL18058348 | 0.92 | MEN1 (0.53) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL13877344 | 0.92 | MEN1 (0.56) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL13877296 | 0.92 | MEN1 (0.56) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL17464068 | 0.92 | MEN1 (0.47) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL15197774 | 0.91 | MEN1 (0.52) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL18310289 | 0.91 | ABCG2 (0.47) | MEN1KMT2AATMWHR1MAPT | |
| SCHEMBL18126099 | 0.90 | MEN1 (0.48) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL22097166 | 0.90 | MEN1 (0.50) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL16946829 | 0.89 | ABCG2 (0.47) | MEN1KMT2AATMWHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090091240-A1 | COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090091240-A1 | COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1808433-A1 | COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2007-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090091240-A1 | COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | INTS9, KCNN2, KCNH3 | MEN1 1940/4885KMT2A 1708/4885ATM 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.